Palisade Bio Inc. (PALI) Announces Exercise for $2.5M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
- AppLovin gains market share among e-commerce advertisers
Palisade Bio Announces Exercise of Previously Issued Warrants for $2.5 Million
January 30, 2024 9:25 AM ESTCarlsbad,CA, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (Palisade or the Company), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced an agreement between the Company and several accredited investors to exercise certain existing warrants (the Existing Warrants) to purchase up to an aggregate of 3,413,286 shares of common stock. The Existing Warrants had initial exercise prices of... More
